Research on the therapeutic effect of nerve growth factor on abnormal GMs infant movement and intelligent structure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012774

Enrollment

Unknown

Registered

2017-09-22

Start date

2017-10-15

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infants with high risk of brain injury

Interventions

control group:early intervention

treatm group:early intervention

treatment:mouse nerve growth factor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The result of GMs is cramped-synchronised (CS) or absence of fidgety movements (F -); 2. Age or corrected age of infants is 15 weeks or under 15 weeks; 3. Except for hereditary metabolic diseases and complicating epilepsy.

Exclusion criteria

Exclusion criteria: 1. Children with uncontrollable seizures; 2. The patient or the patient's guardian refused to accept telephone follow-up or revisits.

Design outcomes

Primary

Measure	Time frame
assessment of general movements;Gross motor function measure;Gesell development schedules;	—

Countries

China

Contacts

Public ContactFeiyong Jia

Department of Developmental and behavioral pediatrics, the First Hospital of Jilin University

erkekangfujia@163.com+86 13943003914

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026